We use cookies to ensure that we give you the best experience on our website Learn more

Home

Saved research

Submission

RETROSPECTIVE COMPARISON OF THE OUTCOME OF PATIENTS, TREATED WITH INTRAVENOUS THROMBOLYSIS WITH UNKNOWN VERSUS KNOWN SYMPTOM ONSET, GUIDED BY CT-IMAGING

Submitted

10 Views
0 Downloads
0 Saves

Presented at

ESOC-2019

-

Presentation

thumbnail

Abstract

Background The WAKE-UP trial showed a favourable outcome of intravenous thrombolysis with alteplase (iv-tPA) in patients with unknown onset of stroke, selected by DWI/FLAIR mismatch on MRI. In many centres, however, acute stroke patients are evaluated by CT-based imaging methods. We aimed at evaluating the outcome and safety of a multimodal CT-based decision making algorithm for iv-tPA in acute stroke patients with unknown symptom onset. Methods Retrospective, single centre analysis. Data from iv-tPA treated patients with unknown symptom onset and from those with a defined symptom onset <4.5 hours were retrieved from the Swiss Stroke Registry (SSR) from July 2014 until May 2018. Patients with endovascular treatment were excluded. Results A mRS score of 0-1 after 90 days was observed in 16/28 patients with unknown symptom onset (57%). The rate of favourable outcome was comparable to patients treated within 4.5 hours after symptom onset (134/272; (49%) p=0.427). There was no difference between the two groups regarding the rates of sICH according to ECASS definition (0/28 vs. 7/272, p=0.395) and death after 3 months (1/28 vs 23/272, p=0.252). Conclusions CT-based selection of patients with unknown symptom onset for iv-tPA is feasible and seems to provide comparable efficacy and safety as in patients treated within the standard time window for iv-tPA of <4.5 hours after symptom onset. Meanwhile the results from the recently finished Extend Australia Study showed a benefit for iv-tPA in patients with wake-up stroke, selected by CT perfusion, compared to placebo.

Datasets

No datasets are available for this submission.

License

No license information is available for this submission.

Company

Legal

Follow us

© Copyright 2019 Morressier GmbH. All rights reserved.

© Copyright 2019 Morressier GmbH.
All rights reserved.